2020
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection
Hummel JP, Maraj I, Taoutel R, Chamoun R, Workman VK, Tran L, Abboud JM, Afif C, Chouairi S, Delvecchio A, Howes CJ, Enriquez AD, Akar JG. Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection. Circulation Arrhythmia And Electrophysiology 2020, 13: e008841-e008841. PMID: 32931318, PMCID: PMC7566294, DOI: 10.1161/circep.120.008841.Peer-Reviewed Original Research
2018
Atrial Fibrillation Thermographic and Endoscopic Monitoring of Patients: Safety Algorithm for the Esophagus
Hummel JP, Kadado AJ, Baker M, Gehi AK, Mounsey JP, Sadaf MI, Enriquez AD, Freeman JV, Akar JG. Atrial Fibrillation Thermographic and Endoscopic Monitoring of Patients: Safety Algorithm for the Esophagus. Circulation Arrhythmia And Electrophysiology 2018, 11: e006814. PMID: 30562101, DOI: 10.1161/circep.118.006814.Peer-Reviewed Original Research
2017
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials
Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. European Heart Journal 2017, 39: 1687-1697. PMID: 28171522, PMCID: PMC6251670, DOI: 10.1093/eurheartj/ehx037.Peer-Reviewed Original ResearchConceptsCardiovascular proceduresClinical trialsNeurological endpointsAcademic Research ConsortiumBenefit-risk assessmentAdjunctive pharmacologyNeurological complicationsNeurological outcomePreventive therapyClinical effectsNeurovascular injuryNeurological injuryNeurological riskEndpoint definitionsCardiovascular interventionsAscertainment methodsTherapyInjuryResearch ConsortiumRiskTrialsEndpointInherent risksSuch proceduresComplications
2016
Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT)
Lip GY, Waldo AL, Ip J, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen M, Halperin JL, Investigators I. Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT). The American Journal Of Cardiology 2016, 118: 1680-1684. PMID: 27665206, DOI: 10.1016/j.amjcard.2016.08.047.Peer-Reviewed Original ResearchConceptsMean therapeutic rangeTherapeutic rangeSAMe-TTAnticoagulation controlDeterminants of timeNew York Heart Association class INew York Heart Association class IVVitamin K antagonist-treated patientsAdditional stroke risk factorsBetter therapeutic rangeGood anticoagulation controlMean TTR valueOverall TTRStroke risk factorsVitamin K antagonistsRisk of strokeNon-US sitesStroke risk assessmentAHRE durationOral anticoagulationK antagonistsOral anticoagulantsRosendaal methodArrhythmia centersAtrial tachyarrhythmias
2009
Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study
Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen MS, Rohani P, Halperin JL, Investigators F. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. American Heart Journal 2009, 158: 364-370.e1. PMID: 19699858, DOI: 10.1016/j.ahj.2009.07.002.Peer-Reviewed Original ResearchConceptsAtrial high-rate episodesRisk of strokeAnticoagulant therapyAtrial fibrillationAtrial flutterCardiac resynchronization therapy-defibrillator deviceConventional clinical managementRemote rhythm monitoringStudies of anticoagulationRate of strokeOral anticoagulant therapyHigh-rate episodesAdditional risk factorsCRT-D devicesStroke risk stratificationCommon cardiac arrhythmiaAHRE burdenElectrocardiographic documentationMajor bleedingSystemic embolismProphylactic therapyClinical characteristicsStroke riskAnticoagulation decisionsClinical features
2007
The Effects of Statins and Renin‐Angiotensin System Blockers on Atrial Fibrillation Recurrence Following Antral Pulmonary Vein Isolation
AL CHEKAKIE M, AKAR JG, WANG F, AL MURADI H, WU J, SANTUCCI P, VARMA N, WILBER DJ. The Effects of Statins and Renin‐Angiotensin System Blockers on Atrial Fibrillation Recurrence Following Antral Pulmonary Vein Isolation. Journal Of Cardiovascular Electrophysiology 2007, 18: 942-946. PMID: 17593228, DOI: 10.1111/j.1540-8167.2007.00887.x.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme InhibitorsAnti-Arrhythmia AgentsAtrial FibrillationCatheter AblationChemotherapy, AdjuvantDrug CombinationsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIllinoisMaleMiddle AgedPrognosisPulmonary VeinsRenin-Angiotensin SystemRisk AssessmentRisk FactorsSecondary PreventionTreatment OutcomeConceptsAngiotensin receptor blockersRenin-angiotensin system blockersAtrial fibrillationEffect of statinsLower AF recurrenceAF recurrenceSystem blockersRecurrence rateRecurrence of AFAntral pulmonary vein isolationAngiotensin system blockersPulmonary vein isolationSubset of patientsCox regression analysisGroup of patientsPersistent atrial fibrillationAnti-inflammatory propertiesMajor treatment optionsRAS blockersReceptor blockersVein isolationConsecutive patientsRetrospective studyTreatment optionsBaseline variables